Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) General Counsel Sells $65,941.96 in Stock

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) General Counsel David O. Watson sold 2,201 shares of Apellis Pharmaceuticals stock in a transaction on Friday, January 17th. The stock was sold at an average price of $29.96, for a total transaction of $65,941.96. Following the completion of the transaction, the general counsel now owns 105,555 shares in the company, valued at $3,162,427.80. This trade represents a 2.04 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

Apellis Pharmaceuticals Trading Up 1.2 %

APLS stock opened at $30.76 on Friday. Apellis Pharmaceuticals, Inc. has a 1-year low of $24.34 and a 1-year high of $71.90. The company has a current ratio of 4.36, a quick ratio of 3.73 and a debt-to-equity ratio of 1.91. The business’s 50 day moving average is $31.95 and its 200-day moving average is $33.25. The firm has a market cap of $3.83 billion, a P/E ratio of -15.15 and a beta of 0.94.

Apellis Pharmaceuticals (NASDAQ:APLS) last announced its quarterly earnings results on Tuesday, November 5th. The company reported ($0.46) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.32) by ($0.14). The company had revenue of $196.83 million during the quarter, compared to the consensus estimate of $200.00 million. Apellis Pharmaceuticals had a negative net margin of 34.97% and a negative return on equity of 103.11%. The business’s revenue was up 78.3% on a year-over-year basis. During the same quarter last year, the company earned ($1.17) earnings per share. Equities analysts anticipate that Apellis Pharmaceuticals, Inc. will post -1.71 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of equities analysts have recently commented on the company. Evercore ISI upgraded Apellis Pharmaceuticals to a “strong-buy” rating in a research note on Thursday, October 31st. Needham & Company LLC cut their price target on Apellis Pharmaceuticals from $85.00 to $60.00 and set a “buy” rating for the company in a report on Wednesday, November 6th. Citigroup reduced their price objective on Apellis Pharmaceuticals from $63.00 to $51.00 and set a “buy” rating for the company in a research report on Wednesday, November 6th. Royal Bank of Canada reaffirmed a “sector perform” rating and set a $26.00 target price on shares of Apellis Pharmaceuticals in a research report on Tuesday. Finally, Oppenheimer reduced their price target on shares of Apellis Pharmaceuticals from $65.00 to $40.00 and set an “outperform” rating for the company in a report on Wednesday, November 6th. Eight equities research analysts have rated the stock with a hold rating, ten have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $46.71.

Institutional Investors Weigh In On Apellis Pharmaceuticals

A number of hedge funds have recently made changes to their positions in APLS. HighVista Strategies LLC grew its stake in Apellis Pharmaceuticals by 4.1% during the second quarter. HighVista Strategies LLC now owns 7,566 shares of the company’s stock worth $290,000 after buying an additional 300 shares during the last quarter. Amalgamated Bank boosted its holdings in shares of Apellis Pharmaceuticals by 5.4% in the 2nd quarter. Amalgamated Bank now owns 6,995 shares of the company’s stock worth $268,000 after acquiring an additional 359 shares in the last quarter. KBC Group NV grew its position in Apellis Pharmaceuticals by 34.8% during the 3rd quarter. KBC Group NV now owns 2,632 shares of the company’s stock worth $76,000 after acquiring an additional 679 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. increased its holdings in Apellis Pharmaceuticals by 21.6% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,404 shares of the company’s stock valued at $130,000 after purchasing an additional 781 shares in the last quarter. Finally, Wolverine Asset Management LLC bought a new position in Apellis Pharmaceuticals in the 3rd quarter valued at $27,000. Institutional investors and hedge funds own 96.29% of the company’s stock.

About Apellis Pharmaceuticals

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).